



FST-100 REDUCES INFECTIOUS ADENOVIRAL TITERS AND IMPROVES CLINICAL SIGNS IN CONJUNCTIVITIS MODEL

- **Statistically significant reduction in adenoviral titers**
- **Statistically significant improvement in clinical signs**
- **No safety issues identified**

NEW YORK, NY, MAY 5, 2010 – Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a widely accepted rabbit model of adenoviral conjunctivitis. Adenoviral titer data demonstrated that FST-100 was able to reduce titers to a greater degree than either saline or Tobradex[®] ($p \leq 0.05$) and was equally as effective as cidofovir. Cidofovir is the standard active control in this model but has shown ocular toxicity in human testing. FST-100 also demonstrated a clinically and statistically significant ($p \leq 0.05$) reduction in signs of adenoviral conjunctivitis versus all other groups tested including saline, Tobradex[®] and cidofovir. The study was conducted at the Louisiana State University (LSU) Health Sciences Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues. Data is being presented at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology being held in Ft. Lauderdale, Florida.

Clinical improvement was seen in some treated rabbits as early as 48 hours after the first dose of FST-100. Complete clinical resolution was observed in all FST-100 treated eyes. No other group reached complete clinical resolution. Specifically, treatment with cidofovir, Tobradex[®] or control resulted in injected and inflamed corneas, eyelid and conjunctival inflammation and injection with sub-conjunctival heme.

Tobradex[®], a commonly prescribed antimicrobial steroid combination product displayed significant adenoviral proliferation (shedding) throughout the treatment phase. This effect is attributable to the dexamethasone component and has been demonstrated in other studies using similar models of adenoviral conjunctivitis. Notably, FST-100 also contains dexamethasone and did not cause adenoviral shedding. In contrast, FST-100 rapidly reduced adenoviral titers.

There is currently no drug that is FDA approved for the treatment of adenoviral conjunctivitis. The disease has the potential to cause a significant amount of patient discomfort and is highly contagious. Adenoviral conjunctivitis is among the most common forms of infectious conjunctivitis worldwide.

The randomized controlled study was conducted in 40 eyes of 20 rabbits experimentally inoculated with human adenovirus type 5. The study was designed to investigate the safety and efficacy of topically administered FST-100 compared to both an active control and inactive control. Animals were randomized 1:1:1:1 (5 rabbits per group) to FST-100, topical 0.5% cidofovir, Tobradex[®] (tobramycin/dexamethasone) ophthalmic suspension and saline. Treatment began one day after viral inoculation and continued for 7 days. Eyes were scored daily for clinical parameters including conjunctival inflammation, fragility of ocular blood vessels, purulent discharge, eyelid inflammation and excessive tearing. Adenoviral titers using a plaque reduction assay were analyzed daily.

Professor Hill commented, “We continue to be impressed with the robust clinical and antiviral activity of FST-100. We are looking forward to testing this drug in our other models of ocular infections.”

About Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics is a drug development company focused on diseases of the eye and ear. The company’s website is: www.foresightbiotherapeutics.com.

For further information contact:

Investor Relations, Foresight Biotherapeutics

646-747-9100 or admin@foresightbio.com

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Foresight relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Foresight’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Foresight and/or its partners to develop, manufacture and commercialize, Foresight’s ability to fund such efforts with or without partners, and other risks.

#